https://pyrexar.com/ 2024-01-22T18:59:23+00:00 1.00 https://pyrexar.com/hyperthermia/product-overview 2024-01-22T18:59:24+00:00 0.80 https://pyrexar.com/hyperthermia/bsd-500 2024-01-22T18:59:25+00:00 0.80 https://pyrexar.com/hyperthermia/bsd-2000 2024-01-22T18:59:26+00:00 0.80 https://pyrexar.com/hyperthermia/bsd-2000-3d 2024-01-22T18:59:27+00:00 0.80 https://pyrexar.com/hyperthermia/bsd-2000-3d-mr 2024-01-22T18:59:28+00:00 0.80 https://pyrexar.com/clinical 2024-01-22T18:59:29+00:00 0.80 https://pyrexar.com/clinical/bsd-2000-clinical-studies 2024-01-22T18:59:30+00:00 0.80 https://pyrexar.com/clinical/clinical-trials 2024-01-22T18:59:31+00:00 0.80 https://pyrexar.com/clinical/by-indication 2024-01-22T18:59:32+00:00 0.80 https://pyrexar.com/knowledgebase/hyperthermia-faq-a 2024-01-22T18:59:33+00:00 0.80 https://pyrexar.com/knowledgebase/pyrexar-video 2024-01-22T18:59:33+00:00 0.80 https://pyrexar.com/knowledgebase/organizations 2024-01-22T18:59:34+00:00 0.80 https://pyrexar.com/knowledgebase/treatment-centers 2024-01-22T18:59:35+00:00 0.80 https://pyrexar.com/knowledgebase/opinion-leaders 2024-01-22T18:59:36+00:00 0.80 https://pyrexar.com/knowledgebase/clinical-training 2024-01-22T18:59:37+00:00 0.80 https://pyrexar.com/hyperthermia-blog 2024-01-22T18:59:38+00:00 0.80 https://pyrexar.com/about-us 2024-01-22T18:59:39+00:00 0.80 https://pyrexar.com/about-us/our-team 2024-01-22T18:59:40+00:00 0.80 https://pyrexar.com/about-us/in-the-news 2024-01-22T18:59:41+00:00 0.80 https://pyrexar.com/about-us/how-to-buy 2024-01-22T18:59:42+00:00 0.80 https://pyrexar.com/about-us/contact-us 2024-01-22T18:59:42+00:00 0.80 https://pyrexar.com/about-us/software-update 2024-01-22T18:59:47+00:00 0.80 https://pyrexar.com/sarcoma-patients-living-longer-with-hyperthermia 2024-01-22T18:59:48+00:00 0.80 https://pyrexar.com/hyperthermia-blog/366-hyperthermia-practice-school-april-15th-16th 2024-01-22T18:59:48+00:00 0.80 https://pyrexar.com/hyperthermia-blog/364-esho-35-review-part-1 2024-01-22T18:59:49+00:00 0.80 https://pyrexar.com/hyperthermia-blog/363-treating-brain-cancer-with-non-invasive-hyperthermia 2024-01-22T18:59:50+00:00 0.80 https://pyrexar.com/hyperthermia-blog/362-exploring-the-intersection-of-modern-cancer-treatment-and-traditional-chinese-medicine-in-china 2024-01-22T18:59:50+00:00 0.80 https://pyrexar.com/hyperthermia-blog/361-pyrexar-ce-renewed 2024-01-22T18:59:51+00:00 0.80 https://pyrexar.com/hyperthermia-blog/360-pancreatic-cancer-study-demonstrates-increase-in-5-year-survival 2024-01-22T18:59:52+00:00 0.80 https://pyrexar.com/privacy-policy 2024-01-22T18:59:53+00:00 0.80 https://pyrexar.com/ifu-login 2024-01-22T18:59:54+00:00 0.64 https://pyrexar.com/hyperthermia-us/bsd-2000 2024-01-22T18:59:55+00:00 0.64 https://pyrexar.com/bsd-2000-family-comparison 2024-01-22T18:59:56+00:00 0.64 https://pyrexar.com/rf-isolation-cage 2024-01-22T18:59:57+00:00 0.64 https://pyrexar.com/component/content/article/34-bladder-cancer-treatment?Itemid=154 2024-01-22T18:59:58+00:00 0.64 https://pyrexar.com/breast 2024-01-22T18:59:59+00:00 0.64 https://pyrexar.com/cervical 2024-01-22T19:00:00+00:00 0.64 https://pyrexar.com/esophageal 2024-01-22T19:00:04+00:00 0.64 https://pyrexar.com/head-neck 2024-01-22T19:00:05+00:00 0.64 https://pyrexar.com/rectal 2024-01-22T19:00:06+00:00 0.64 https://pyrexar.com/sarcoma 2024-01-22T19:00:07+00:00 0.64 https://pyrexar.com/clinical/by-indication/34-bladder-cancer-treatment 2024-01-22T19:00:08+00:00 0.64 https://pyrexar.com/clinical/bsd-2000-clinical-studies/346-abdominal 2024-01-22T19:00:08+00:00 0.64 https://pyrexar.com/clinical/bsd-2000-clinical-studies/347-breast 2024-01-22T19:00:10+00:00 0.64 https://pyrexar.com/clinical/bsd-2000-clinical-studies/343-bladder 2024-01-22T19:00:11+00:00 0.64 https://pyrexar.com/clinical/bsd-2000-clinical-studies/349-cervical 2024-01-22T19:00:13+00:00 0.64 https://pyrexar.com/clinical/bsd-2000-clinical-studies/351-ovarian 2024-01-22T19:00:16+00:00 0.64 https://pyrexar.com/clinical/bsd-2000-clinical-studies/352-pancreatic 2024-01-22T19:00:17+00:00 0.64 https://pyrexar.com/clinical/bsd-2000-clinical-studies/354-pediatric 2024-01-22T19:00:18+00:00 0.64 https://pyrexar.com/clinical/bsd-2000-clinical-studies/345-pelvic 2024-01-22T19:00:20+00:00 0.64 https://pyrexar.com/clinical/bsd-2000-clinical-studies/353-prostate 2024-01-22T19:00:22+00:00 0.64 https://pyrexar.com/clinical/bsd-2000-clinical-studies/356-rectal 2024-01-22T19:00:22+00:00 0.64 https://pyrexar.com/clinical/bsd-2000-clinical-studies/348-sarcoma 2024-01-22T19:00:24+00:00 0.64 https://pyrexar.com/clinical/bsd-2000-clinical-studies/350-general-technical 2024-01-22T19:00:27+00:00 0.64 https://pyrexar.com/about-us-2/featured-event 2024-01-22T19:00:31+00:00 0.64 https://pyrexar.com/pediatric 2024-01-22T19:00:34+00:00 0.64 https://pyrexar.com/anal 2024-01-22T19:00:35+00:00 0.64 https://pyrexar.com/clinical/by-indication?start=4 2024-01-22T19:00:36+00:00 0.64 https://pyrexar.com/clinical/by-indication?start=8 2024-01-22T19:00:36+00:00 0.64 https://pyrexar.com/faq-general 2024-01-22T19:00:37+00:00 0.64 https://pyrexar.com/faq-500-superficial 2024-01-22T19:00:38+00:00 0.64 https://pyrexar.com/faq-2000 2024-01-22T19:00:38+00:00 0.64 https://pyrexar.com/faq-2000-3d-mr 2024-01-22T19:00:39+00:00 0.64 https://pyrexar.com/knowledgebase/organizations?start=20 2024-01-22T19:00:40+00:00 0.64 https://pyrexar.com/knowledgebase-us/opinion-leaders/288-harnessing-heat-for-diagnosis-and-therapy 2024-01-22T19:00:41+00:00 0.64 https://pyrexar.com/bsd-500-training 2024-01-22T19:00:41+00:00 0.64 https://pyrexar.com/knowledgebase/clinical-training?view=article&id=338:cme-course-2021&catid=2 2024-01-22T19:00:42+00:00 0.64 https://pyrexar.com/hyperthermia-blog/358-first-combined-hyperthermia-proton-center-established-in-china 2024-01-22T19:00:45+00:00 0.64 https://pyrexar.com/hyperthermia-blog/341-hyperthermia-practice-school-october-29-30-2021 2024-01-22T19:00:45+00:00 0.64 https://pyrexar.com/hyperthermia-blog/342-new-image-guided-hyperthermia-open-in-tuebingen 2024-01-22T19:00:46+00:00 0.64 https://pyrexar.com/hyperthermia-blog/340-china-s-largest-hospital-chooses-pyrexar 2024-01-22T19:00:47+00:00 0.64 https://pyrexar.com/hyperthermia-blog/339-impact-of-hyperthermia-in-the-treatment-of-soft-tissue-sarcomas 2024-01-22T19:00:48+00:00 0.64 https://pyrexar.com/hyperthermia-blog/335-2020-esho-pyrexar-award-recipient 2024-01-22T19:00:48+00:00 0.64 https://pyrexar.com/hyperthermia-blog/334-clinical-studies-still-in-process 2024-01-22T19:00:50+00:00 0.64 https://pyrexar.com/hyperthermia-blog/330-ivy-lab-promoted-to-master-distributor 2024-01-22T19:00:50+00:00 0.64 https://pyrexar.com/hyperthermia-blog/329-wanfang-adds-new-system-to-thermal-oncology-practice 2024-01-22T19:00:51+00:00 0.64 https://pyrexar.com/hyperthermia-blog/327-selecting-your-mri-for-image-guided-hyperthermia 2024-01-22T19:00:52+00:00 0.64 https://pyrexar.com/hyperthermia-blog/328-can-you-imagine-an-in-person-trade-event 2024-01-22T19:00:53+00:00 0.64 https://pyrexar.com/hyperthermia-blog/326-paving-the-way-for-brain-cancer-treatment 2024-01-22T19:00:53+00:00 0.64 https://pyrexar.com/hyperthermia-blog/325-pyrexar-awarded-us-patent-for-brain-treatment-device 2024-01-22T19:00:54+00:00 0.64 https://pyrexar.com/hyperthermia-blog/324-study-outlines-the-benefits-of-hyperthermia-for-mibc-patients 2024-01-22T19:00:55+00:00 0.64 https://pyrexar.com/hyperthermia-blog/322-new-study-shows-breast-cancer-treatment-improvement-with-hyperthermia 2024-01-22T19:00:55+00:00 0.64 https://pyrexar.com/hyperthermia-blog/321-trilogy-of-cancer-technologies-at-ummc 2024-01-22T19:00:56+00:00 0.64 https://pyrexar.com/hyperthermia-blog/320-trade-events-spring-2020 2024-01-22T19:00:57+00:00 0.64 https://pyrexar.com/hyperthermia-blog/319-34th-german-cancer-congress 2024-01-22T19:00:57+00:00 0.64 https://pyrexar.com/hyperthermia-blog?start=14 2024-01-22T19:00:58+00:00 0.64 https://pyrexar.com/hyperthermia-blog?start=28 2024-01-22T19:00:59+00:00 0.64 https://pyrexar.com/hyperthermia-blog?start=42 2024-01-22T19:01:00+00:00 0.64 https://pyrexar.com/hyperthermia-blog?start=56 2024-01-22T19:01:01+00:00 0.64 https://pyrexar.com/hyperthermia-blog?start=70 2024-01-22T19:01:02+00:00 0.64 https://pyrexar.com/hyperthermia-blog?start=84 2024-01-22T19:01:02+00:00 0.64 https://pyrexar.com/hyperthermia-blog?start=98 2024-01-22T19:01:03+00:00 0.64 https://pyrexar.com/hyperthermia-blog?start=112 2024-01-22T19:01:04+00:00 0.64 https://pyrexar.com/hyperthermia-blog?start=126 2024-01-22T19:01:05+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/274-frost-sullivan-recognizes-bsd-medical-s-technology-innovation-in-cancer-therapy-devices 2024-01-22T19:01:06+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/272-high-precision-proton-therapy-more-effective-in-treating-certain-cancers-when-combined-with-thermal-therapy 2024-01-22T19:01:06+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/135-pyrexar-medical-buys-back-outside-ownership 2024-01-22T19:01:07+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/131-pyrexar-brings-cancer-treatment-options-to-taiwan 2024-01-22T19:01:08+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/130-spain-warming-to-the-use-of-hyperthermia-in-cancer-treatment 2024-01-22T19:01:08+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/128-pyrexar-returns-hyperthermia-to-egypt-after-5000-years 2024-01-22T19:01:09+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/122-pyrexar-medical-heats-up-chicago-at-the-rsna 2024-01-22T19:01:10+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/121-pyrexar-presents-at-the-workshop-on-hadron-therapy-in-chiapas-mexico 2024-01-22T19:01:10+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/115-pyrexar-medical-brings-the-thermal-therapy-message-to-astro 2024-01-22T19:01:11+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/113-pyrexar-helps-spain-lead-the-way-in-thermal-therapy 2024-01-22T19:01:11+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/110-pyrexar-medical-moves-into-new-headquarters 2024-01-22T19:01:12+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/111-pyrexar-helps-south-korea-lead-the-way-in-cancer-therapy 2024-01-22T19:01:13+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/105-pyrexar-brings-the-fight-against-cancer-to-south-korea 2024-01-22T19:01:13+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/103-pyrexar-medical-expands-hyperthermia-to-central-asia 2024-01-22T19:01:14+00:00 0.64 https://pyrexar.com/about-us-2/in-the-news/86-pyrexar-chief-scientist-goes-to-china 2024-01-22T19:01:15+00:00 0.64 https://pyrexar.com/about-us/in-the-news?start=10 2024-01-22T19:01:15+00:00 0.64 https://pyrexar.com/knowledgebase-us 2024-01-22T19:01:22+00:00 0.64 https://pyrexar.com/asmed-contact 2024-01-22T19:01:23+00:00 0.64 https://pyrexar.com/component/users/reset?Itemid=101 2024-01-22T19:01:24+00:00 0.64 https://pyrexar.com/component/users/remind?Itemid=101 2024-01-22T19:01:25+00:00 0.64 https://pyrexar.com/free-issue-of-ijh 2024-01-22T19:01:26+00:00 0.64 https://pyrexar.com/pyrexar-expands-into-13-countries 2024-01-22T19:01:27+00:00 0.64 https://pyrexar.com/about-us-2/how-to-buy 2024-01-22T19:01:27+00:00 0.64 https://pyrexar.com/ifu-login?view=reset 2024-01-22T19:01:28+00:00 0.51 https://pyrexar.com/ifu-login?view=remind 2024-01-22T19:01:29+00:00 0.51 https://pyrexar.com/home-us 2024-01-22T19:01:29+00:00 0.51 https://pyrexar.com/hyperthermia-us/bsd-500 2024-01-22T19:01:30+00:00 0.51 https://pyrexar.com/clinical-us 2024-01-22T19:01:31+00:00 0.51 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies 2024-01-22T19:01:31+00:00 0.51 https://pyrexar.com/clinical-us/clinical-trials 2024-01-22T19:01:32+00:00 0.51 https://pyrexar.com/knowledgebase-us/pyrexar-video-us 2024-01-22T19:01:36+00:00 0.51 https://pyrexar.com/knowledgebase-us/organizations 2024-01-22T19:01:36+00:00 0.51 https://pyrexar.com/knowledgebase-us/treatment-centers 2024-01-22T19:01:37+00:00 0.51 https://pyrexar.com/knowledgebase-us/hyperthermia-faq 2024-01-22T19:01:38+00:00 0.51 https://pyrexar.com/knowledgebase-us/opinion-leaders 2024-01-22T19:01:39+00:00 0.51 https://pyrexar.com/about-us-2 2024-01-22T19:01:39+00:00 0.51 https://pyrexar.com/about-us-2/our-team 2024-01-22T19:01:40+00:00 0.51 https://pyrexar.com/about-us-2/in-the-news 2024-01-22T19:01:41+00:00 0.51 https://pyrexar.com/about-us-2/2015-05-18-18-23-51 2024-01-22T19:01:41+00:00 0.51 https://pyrexar.com/blog-us 2024-01-22T19:01:42+00:00 0.51 https://pyrexar.com/bsd-2000-family-comparison?view=article&id=72:bsd-2000-3d-more-info&catid=18 2024-01-22T19:01:43+00:00 0.51 https://pyrexar.com/uofm 2024-01-22T19:01:44+00:00 0.51 https://pyrexar.com/knowledgebase/organizations?start=0 2024-01-22T19:01:48+00:00 0.51 https://pyrexar.com/knowledgebase/clinical-training?view=article&id=293:search-results&catid=2 2024-01-22T19:01:49+00:00 0.51 https://pyrexar.com/hyperthermia-blog/318-iahom-indian-association-of-hyperthermic-oncology-and-medicine 2024-01-22T19:01:50+00:00 0.51 https://pyrexar.com/heat-release-drugs-move-forward 2024-01-22T19:01:50+00:00 0.51 https://pyrexar.com/thermal-oncology-team-training-hanoi 2024-01-22T19:01:52+00:00 0.51 https://pyrexar.com/hyperthermia-in-rome 2024-01-22T19:01:53+00:00 0.51 https://pyrexar.com/protons-protons-protons 2024-01-22T19:01:54+00:00 0.51 https://pyrexar.com/u-of-m-proton-center-celebrates-milestone 2024-01-22T19:01:54+00:00 0.51 https://pyrexar.com/protons-vs-carbon-ions 2024-01-22T19:01:55+00:00 0.51 https://pyrexar.com/busy-week-for-hyperthermia 2024-01-22T19:01:56+00:00 0.51 https://pyrexar.com/hyperthermia-blog/302-seor-spain-2019 2024-01-22T19:01:57+00:00 0.51 https://pyrexar.com/pyrexar-at-abs 2024-01-22T19:01:58+00:00 0.51 https://pyrexar.com/esho-33 2024-01-22T19:01:59+00:00 0.51 https://pyrexar.com/hyperthermia-blog/298-stm-presents-its-top-awards 2024-01-22T19:01:59+00:00 0.51 https://pyrexar.com/hyperthermia-experts-gather-in-milan 2024-01-22T19:02:00+00:00 0.51 https://pyrexar.com/hyperthermia-blog/295-stm-esho-event-reminder-4 2024-01-22T19:02:01+00:00 0.51 https://pyrexar.com/hyperthermia-proton-beam 2024-01-22T19:02:02+00:00 0.51 https://pyrexar.com/component/gantry5/?Itemid=108 2024-01-22T19:02:04+00:00 0.51 https://pyrexar.com/component/content/article/276-visit-us-next?Itemid=194 2024-01-22T19:02:06+00:00 0.51 https://pyrexar.com/four-year-anniversary 2024-01-22T19:02:07+00:00 0.51 https://pyrexar.com/st-john-ascension-adds-hyperthermia 2024-01-22T19:02:08+00:00 0.51 https://pyrexar.com/stm-adds-clinical-hyperthermia 2024-01-22T19:02:08+00:00 0.51 https://pyrexar.com/images/social/STM2019%20-%20%20Clinical%20hyperthermia%20practice%20guidelines%20workshop%20v11%20%20030519.pdf 2019-03-11T18:07:43+00:00 0.51 https://pyrexar.com/siteman-cancer-center-chooses-pyrexar 2024-01-22T19:02:10+00:00 0.51 https://pyrexar.com/bringing-thought-leaders-together 2024-01-22T19:02:11+00:00 0.51 https://pyrexar.com/stm-esho-2019 2024-01-22T19:02:12+00:00 0.51 https://pyrexar.com/hyperthermia-blog/285-bringing-advanced-cancer-treatment-to-india 2024-01-22T19:02:12+00:00 0.51 https://pyrexar.com/the-impact-of-personal-stories 2024-01-22T19:02:13+00:00 0.51 https://pyrexar.com/abc-news-2018-part-5 2024-01-22T19:02:14+00:00 0.51 https://pyrexar.com/abc-news-2018-part-4 2024-01-22T19:02:15+00:00 0.51 https://pyrexar.com/abc-news-2018-part-3 2024-01-22T19:02:16+00:00 0.51 https://pyrexar.com/abc-news-2018-part-2 2024-01-22T19:02:17+00:00 0.51 https://pyrexar.com/abc-news-2018-part-1 2024-01-22T19:02:17+00:00 0.51 https://pyrexar.com/tastro-a-success-in-taiwan 2024-01-22T19:02:18+00:00 0.51 https://pyrexar.com/astro-2018-in-review 2024-01-22T19:02:20+00:00 0.51 https://pyrexar.com/new-study-supporting-focus-and-steering 2024-01-22T19:02:21+00:00 0.51 https://pyrexar.com/2018-website-update 2024-01-22T19:02:23+00:00 0.51 https://pyrexar.com/wan-fang-opens-their-doors-to-share-hyperthermia 2024-01-22T19:02:24+00:00 0.51 https://pyrexar.com/visit-us-at-astro-2018 2024-01-22T19:02:25+00:00 0.51 https://pyrexar.com/pyrexar-adds-thailand-distributor 2024-01-22T19:02:26+00:00 0.51 https://pyrexar.com/pyrexar-signs-with-viet-nam 2024-01-22T19:02:27+00:00 0.51 https://pyrexar.com/stm-2018-review 2024-01-22T19:02:28+00:00 0.51 https://pyrexar.com/hyperthermia-to-vi-t-nam 2024-01-22T19:02:28+00:00 0.51 https://pyrexar.com/bringing-hyperthermia-to-kuwait 2024-01-22T19:02:29+00:00 0.51 https://pyrexar.com/esho-2018-update 2024-01-22T19:02:30+00:00 0.51 https://pyrexar.com/hyperthermia-blog/199-stm-esho-event-reminder-2 2024-01-22T19:02:31+00:00 0.51 https://pyrexar.com/stm-esho-2018 2024-01-22T19:02:32+00:00 0.51 https://pyrexar.com/pyrexar-entering-middle-east 2024-01-22T19:02:33+00:00 0.51 https://pyrexar.com/where-have-you-been-india 2024-01-22T19:02:34+00:00 0.51 https://pyrexar.com/new-distributor-in-japan 2024-01-22T19:02:35+00:00 0.51 https://pyrexar.com/ptho-congress-was-a-great-success 2024-01-22T19:02:36+00:00 0.51 https://pyrexar.com/bsd-2000-3d-mr-system-now-in-service 2024-01-22T19:02:37+00:00 0.51 https://pyrexar.com/is-there-a-future-for-capacitive-hyperthermia 2024-01-22T19:02:37+00:00 0.51 https://pyrexar.com/south-korea-astro-jca 2024-01-22T19:02:38+00:00 0.51 https://pyrexar.com/taiwan-partners-and-water 2024-01-22T19:02:39+00:00 0.51 https://pyrexar.com/ptho-congress-2017 2024-01-22T19:02:40+00:00 0.51 https://pyrexar.com/kirloskar-group-brings-hyperthermia-cancer-treatment-to-india 2024-01-22T19:02:41+00:00 0.51 https://pyrexar.com/recent-visit-to-china 2024-01-22T19:02:42+00:00 0.51 https://pyrexar.com/saudi-cancer-foundation-brings-hyperthermia-awareness-to-ksa 2024-01-22T19:02:47+00:00 0.51 https://pyrexar.com/hyperthermia-takes-center-stage-in-south-korea 2024-01-22T19:02:47+00:00 0.51 https://pyrexar.com/stm-2017-highlights 2024-01-22T19:02:48+00:00 0.51 https://pyrexar.com/abc-news-part-5 2024-01-22T19:02:49+00:00 0.51 https://pyrexar.com/abc-news-part-1 2024-01-22T19:02:50+00:00 0.51 https://pyrexar.com/abc-news-part-2 2024-01-22T19:02:50+00:00 0.51 https://pyrexar.com/abc-news-part-3 2024-01-22T19:02:51+00:00 0.51 https://pyrexar.com/abc-news-part-4 2024-01-22T19:02:52+00:00 0.51 https://pyrexar.com/study-shows-capacitve-heating-the-poor-choice 2024-01-22T19:02:53+00:00 0.51 https://pyrexar.com/join-us-at-stm-2017 2024-01-22T19:02:53+00:00 0.51 https://pyrexar.com/hyperthermia-blog/164-the-future-of-radiation-therapy-in-peril 2024-01-22T19:02:54+00:00 0.51 https://pyrexar.com/booth 2024-01-22T19:02:55+00:00 0.51 https://pyrexar.com/world-s-largest-hospital-supporting-hyperthermia 2024-01-22T19:02:56+00:00 0.51 https://pyrexar.com/robots-invade-astro-2016 2024-01-22T19:02:56+00:00 0.51 https://pyrexar.com/astro-hyperthermia-and-rvus 2024-01-22T19:02:57+00:00 0.51 https://pyrexar.com/astro-setup-day 2024-01-22T19:02:58+00:00 0.51 https://pyrexar.com/hyperthermia-blog/157-as-american-as-baseballs-apple-and-pie 2024-01-22T19:02:59+00:00 0.51 https://pyrexar.com/ht-rt-beats-ct-rt-in-advanced-cervical-cancer 2024-01-22T19:02:59+00:00 0.51 https://pyrexar.com/component/content/featured?Itemid=194 2024-01-22T19:03:00+00:00 0.51 https://pyrexar.com/visit-astro-2016 2024-01-22T19:03:01+00:00 0.51 https://pyrexar.com/hyperthermia-blog/154-pyrexar-super-user-receives-award-for-hyperthermic-oncology-research 2024-01-22T19:03:02+00:00 0.51 https://pyrexar.com/where-is-the-evidence 2024-01-22T19:03:02+00:00 0.51 https://pyrexar.com/last-week-at-asco 2024-01-22T19:03:03+00:00 0.51 https://pyrexar.com/hyperthermia-blog/150-abc-news-report-on-hyperthermia-promo 2024-01-22T19:03:04+00:00 0.51 https://pyrexar.com/hyperthermia-blog/145-pyrexar-presents-lifetime-achievement-awards-at-icho 2024-01-22T19:03:05+00:00 0.51 https://pyrexar.com/pyrexar-day-2016-update 2024-01-22T19:03:05+00:00 0.51 https://pyrexar.com/pyrexar-celebrates-its-first-year 2024-01-22T19:03:06+00:00 0.51 https://pyrexar.com/ce-lebration-at-pyrexar 2024-01-22T19:03:07+00:00 0.51 https://pyrexar.com/hyperthermia-blog/139-new-speakers-added-to-pyrexar-day-schedule 2024-01-22T19:03:08+00:00 0.51 https://pyrexar.com/pyrexar-preparing-to-bring-hyperthermia-cancer-therapy-to-cuba 2024-01-22T19:03:09+00:00 0.51 https://pyrexar.com/today-s-big-deal-is-a-big-deal 2024-01-22T19:03:10+00:00 0.51 https://pyrexar.com/treating-patients-with-hyperthermia-in-new-taipei-city 2024-01-22T19:03:11+00:00 0.51 https://pyrexar.com/magna-medic-making-a-difference-in-spain 2024-01-22T19:03:11+00:00 0.51 https://pyrexar.com/city-of-dubai-like-no-other 2024-01-22T19:03:12+00:00 0.51 https://pyrexar.com/hyperthermia-blog/126-benefits-of-hyperthermia-for-head-and-neck-cancers 2024-01-22T19:03:13+00:00 0.51 https://pyrexar.com/pyrexar-in-the-wall-street-journal 2024-01-22T19:03:14+00:00 0.51 https://pyrexar.com/rsna-2015-in-review 2024-01-22T19:03:15+00:00 0.51 https://pyrexar.com/pyrexar-heading-to-the-rsna 2024-01-22T19:03:15+00:00 0.51 https://pyrexar.com/pyrexar-presents-at-the-workshop-on-hadron-therapy 2024-01-22T19:03:16+00:00 0.51 https://pyrexar.com/astro-2015-in-review 2024-01-22T19:03:17+00:00 0.51 https://pyrexar.com/drones-vs-cranes 2024-01-22T19:03:18+00:00 0.51 https://pyrexar.com/put-another-star-on-the-map-spain 2024-01-22T19:03:19+00:00 0.51 https://pyrexar.com/pyrexar-medical-moves-into-new-headquarters 2024-01-22T19:03:20+00:00 0.51 https://pyrexar.com/about-us/in-the-news/128-pyrexar-returns-hyperthermia-to-egypt-after-5000-years 2024-01-22T19:03:21+00:00 0.51 https://pyrexar.com/have-you-seen-the-stapler 2024-01-22T19:03:21+00:00 0.51 https://pyrexar.com/deep-regional-hyperhtermia-arrives-in-south-korea 2024-01-22T19:03:22+00:00 0.51 https://pyrexar.com/first-scratch-build-completed 2024-01-22T19:03:23+00:00 0.51 https://pyrexar.com/about-us/in-the-news/105-pyrexar-brings-the-fight-against-cancer-to-south-korea 2024-01-22T19:03:24+00:00 0.51 https://pyrexar.com/my-father-died-today 2024-01-22T19:03:25+00:00 0.51 https://pyrexar.com/hyperthermia-blog/101-these-are-not-the-droids-you-re-looking-for 2024-01-22T19:03:26+00:00 0.51 https://pyrexar.com/nanotechnology-for-treating-cancer-is-here 2024-01-22T19:03:26+00:00 0.51 https://pyrexar.com/vrba-takes-home-2015-esho-pyrexar-award 2024-01-22T19:03:27+00:00 0.51 https://pyrexar.com/hyperthermia-finds-hopeful-results-for-pancreatic-cancer-at-ctca 2024-01-22T19:03:28+00:00 0.51 https://pyrexar.com/top-researcher-review-hypethermia-results 2024-01-22T19:03:29+00:00 0.51 https://pyrexar.com/all-over-the-map 2024-01-22T19:03:30+00:00 0.51 https://pyrexar.com/hyperthermia-shrinks-tumors-at-tvroc 2024-01-22T19:03:31+00:00 0.51 https://pyrexar.com/china-s-fight-against-cancer 2024-01-22T19:03:32+00:00 0.51 https://pyrexar.com/how-superficial-hyperthermia-works 2024-01-22T19:03:33+00:00 0.51 https://pyrexar.com/how-deep-regional-hyperthermia-works 2024-01-22T19:03:33+00:00 0.51 https://pyrexar.com/hyperthermia-blog/81-what-i-learned-at-stm 2024-01-22T19:03:34+00:00 0.51 https://pyrexar.com/stm2015 2024-01-22T19:03:35+00:00 0.51 https://pyrexar.com/putting-the-heat-on-tumors 2024-01-22T19:03:36+00:00 0.51 https://pyrexar.com/hyperthermia-blog/74-hyperthermia-therapy-at-ctca 2024-01-22T19:03:37+00:00 0.51 https://pyrexar.com/about-us-2/in-the-news/77-pyrexar-medical-closes-deal-with-hanbeam-technology 2024-01-22T19:03:37+00:00 0.51 https://pyrexar.com/about-us-2/in-the-news/68-pyrexar-medical-acquires-hyperthermia-assets-of-bsd-medical 2024-01-22T19:03:38+00:00 0.51 https://pyrexar.com/knowledgebase-us?view=article&id=31:science-of-hyperthermia&catid=16 2024-01-22T19:03:39+00:00 0.51 https://pyrexar.com/study 2024-01-22T19:03:39+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/243-neo-adjuvant-chemotherapy-alone-or-with-regional-hyperthermia-for-localised-high-risk-soft-tissue-sarcoma-a-randomised-phase-3-multicentre-study 2024-01-22T19:03:40+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/262-the-dutch-deep-hyperthermia-trial-results-in-cervical-cancer 2024-01-22T19:03:41+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/232-long-term-improvement-in-treatment-outcome-after-radiotherapy-and-hyperthermia-in-locoregionally-advanced-cervix-cancer-an-update-of-the-dutch-deep-hyperthermia-trial 2024-01-22T19:03:42+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/237-radiotherapy-and-hyperthermia-for-treatment-of-primary-locally-advanced-cervix-cancer-results-in-378-patients 2024-01-22T19:03:42+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/231-comparison-of-radiotherapy-alone-with-radiotherapy-plus-hyperthermia-in-locally-advanced-pelvic-tumours-a-prospective-randomised-multicentre-trial-dutch-deep-hyperthermia-group 2024-01-22T19:03:43+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/249-effectiveness-of-regional-hyperthermia-with-chemotherapy-for-high-risk-retroperitoneal-and-abdominal-soft-tissue-sarcoma-after-complete-surgical-resection 2024-01-22T19:03:44+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/242-effect-of-neoadjuvant-chemotherapy-plus-regional-hyperthermia-on-long-term-outcomes-among-patients-with-localized-high-risk-soft-tissue-sarcoma-the-eortc-62961-esho-95-randomized-clinical-trial 2024-01-22T19:03:44+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/261-regional-hyperthermia-in-patients-with-recurrent-genitourinary-cancer 2024-01-22T19:03:45+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/259-radiochemotherapy-in-combination-with-regional-hyperthermia-in-preirradiated-patients-with-recurrent-rectal-cancer 2024-01-22T19:03:46+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/263-external-validation-of-a-rectal-cancer-outcome-prediction-model-with-a-cohort-of-patients-treated-with-preoperative-radiochemotherapy-and-deep-regional-hyperthermia 2024-01-22T19:03:46+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies?start=7 2024-01-22T19:03:47+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies?start=14 2024-01-22T19:03:48+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies?start=21 2024-01-22T19:03:48+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies?start=28 2024-01-22T19:03:49+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies?start=35 2024-01-22T19:03:50+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies?start=42 2024-01-22T19:03:51+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies?start=49 2024-01-22T19:03:51+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies?start=56 2024-01-22T19:03:52+00:00 0.41 https://pyrexar.com/knowledgebase-us/hyperthermia-faq?view=article&id=31:science-of-hyperthermia&catid=16 2024-01-22T19:03:53+00:00 0.41 https://pyrexar.com/about-us-2/in-the-news?start=10 2024-01-22T19:03:53+00:00 0.41 https://pyrexar.com/blog-us?start=4 2024-01-22T19:03:54+00:00 0.41 https://pyrexar.com/blog-us?start=8 2024-01-22T19:03:55+00:00 0.41 https://pyrexar.com/blog-us?start=12 2024-01-22T19:03:56+00:00 0.41 https://pyrexar.com/blog-us?start=16 2024-01-22T19:03:56+00:00 0.41 https://pyrexar.com/blog-us?start=20 2024-01-22T19:03:57+00:00 0.41 https://pyrexar.com/blog-us?start=24 2024-01-22T19:03:58+00:00 0.41 https://pyrexar.com/component/content/featured?Itemid=101&start=4 2024-01-22T19:03:59+00:00 0.41 https://pyrexar.com/component/content/featured?Itemid=101&start=8 2024-01-22T19:04:00+00:00 0.41 https://pyrexar.com/stm2015?view=article&id=98:welcome-to-pyrexar-medical&catid=21 2024-01-22T19:04:01+00:00 0.41 https://pyrexar.com/stm2015?view=article&id=80:esho-european-society-of-thermal-medicine&catid=21 2024-01-22T19:04:02+00:00 0.41 https://pyrexar.com/knowledgebase-us?view=article&id=26:sales-agency&catid=16 2024-01-22T19:04:02+00:00 0.41 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/257-gemcitabine-and-cisplatin-combined-with-regional-hyperthermia-as-second-line-treatment-in-patients-with-gemcitabine-refractory-advanced-pancreatic-cancer 2024-01-22T19:04:03+00:00 0.33 https://pyrexar.com/component/tags/tag/radiotherapy 2024-01-22T19:04:04+00:00 0.33 https://pyrexar.com/component/tags/tag/chemotherapy 2024-01-22T19:04:05+00:00 0.33 https://pyrexar.com/component/tags/tag/bsd-2000 2024-01-22T19:04:06+00:00 0.33 https://pyrexar.com/component/tags/tag/soft-tissue-sarcoma 2024-01-22T19:04:06+00:00 0.33 https://pyrexar.com/component/tags/tag/phase-iii 2024-01-22T19:04:07+00:00 0.33 https://pyrexar.com/component/tags/tag/cervical 2024-01-22T19:04:08+00:00 0.33 https://pyrexar.com/component/tags/tag/bladder 2024-01-22T19:04:09+00:00 0.33 https://pyrexar.com/component/tags/tag/rectal 2024-01-22T19:04:10+00:00 0.33 https://pyrexar.com/component/tags/tag/brachytherapy 2024-01-22T19:04:11+00:00 0.33 https://pyrexar.com/component/tags/tag/pelvic 2024-01-22T19:04:12+00:00 0.33 https://pyrexar.com/component/tags/tag/phase-ii 2024-01-22T19:04:12+00:00 0.33 https://pyrexar.com/component/tags/tag/genitourinary 2024-01-22T19:04:13+00:00 0.33 https://pyrexar.com/component/tags/tag/surgery 2024-01-22T19:04:14+00:00 0.33 https://pyrexar.com/component/tags/tag/analysis 2024-01-22T19:04:15+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/258-intra-peritoneal-cisplatin-and-whole-abdomen-hyperthermia-for-relapsed-ovarian-carcinoma 2024-01-22T19:04:16+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/208-ifosfamide-carboplatin-and-etoposide-ice-as-second-line-regimen-alone-and-in-combination-with-regional-hyperthermia-is-active-in-chemo-pre-treated-advanced-soft-tissue-sarcoma-of-adults 2024-01-22T19:04:17+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/250-methods-and-potentials-of-magnetic-resonance-imaging-for-monitoring-radiofrequency-hyperthermia-in-a-hybrid-system 2024-01-22T19:04:17+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/248-a-phase-ii-trial-testing-the-thermal-dose-parameter-cem43-degrees-t90-as-a-predictor-of-response-in-soft-tissue-sarcomas-treated-with-pre-operative-thermoradiotherapy 2024-01-22T19:04:18+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/247-conformal-radiotherapy-plus-local-hyperthermia-in-patients-affected-by-locally-advanced-high-risk-prostate-cancer-preliminary-results-of-a-prospective-phase-ii-study 2024-01-22T19:04:19+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/246-neoadjuvant-chemotherapy-followed-by-radiotherapy-and-concurrent-hyperthermia-in-patients-with-advanced-stage-cervical-cancer-a-retrospective-study 2024-01-22T19:04:19+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/245-regional-hyperthermia-combined-with-chemoradiotherapy-in-primary-or-recurrent-locally-advanced-pancreatic-cancer-an-open-label-comparative-cohort-trial 2024-01-22T19:04:20+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/244-treatment-of-recurrent-malignant-sacrococcygeal-germ-cell-tumors-analysis-of-22-patients-registered-in-the-german-protocols-makei-83-86-89-and-96 2024-01-22T19:04:20+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/241-regional-hyperthermia-added-to-intensified-preoperative-chemo-radiation-in-locally-advanced-adenocarcinoma-of-middle-and-lower-rectum 2024-01-22T19:04:21+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/240-regional-abdominal-hyperthermia-combined-with-systemic-chemotherapy-for-the-treatment-of-patients-with-ovarian-cancer-relapse-results-of-a-pilot-study 2024-01-22T19:04:22+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/239-thermochemotherapy-in-patients-with-extremity-high-risk-soft-tissue-sarcomas-hr-sts 2024-01-22T19:04:22+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/238-quadrimodal-treatment-of-high-risk-t1-and-t2-bladder-cancer-transurethral-tumor-resection-followed-by-concurrent-radiochemotherapy-and-regional-deep-hyperthermia 2024-01-22T19:04:23+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/236-clinical-outcome-after-neoadjuvant-thermoradiotherapy-in-high-grade-soft-tissue-sarcomas 2024-01-22T19:04:24+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/235-secondary-external-beam-radiotherapy-and-hyperthermia-for-local-recurrence-after-125-iodine-implantation-in-adenocarcinoma-of-the-prostate 2024-01-22T19:04:24+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/234-phantom-studies-and-preliminary-clinical-experience-with-the-bsd-2000 2024-01-22T19:04:25+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/233-an-approach-for-cure-pei-chemotherapy-and-regional-deep-hyperthermia-in-children-and-adolescents-with-unresectable-malignant-tumors 2024-01-22T19:04:26+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/230-long-term-survival-data-of-triple-modality-treatment-of-stage-iib-iii-iva-cervical-cancer-with-the-combination-of-radiotherapy-chemotherapy-and-hyperthermia-an-update 2024-01-22T19:04:27+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/229-first-results-of-triple-modality-treatment-combining-radiotherapy-chemotherapy-and-hyperthermia-for-the-treatment-of-patients-with-stage-iib-iii-and-iva-cervical-carcinoma 2024-01-22T19:04:27+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/228-hyperthermia-for-the-treatment-of-patients-with-malignant-germ-cell-tumors-a-phase-i-ii-study-in-ten-children-and-adolescents-with-recurrent-or-refractory-tumors 2024-01-22T19:04:28+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/227-treatment-results-in-children-and-adolescents-with-loco-regional-recurrences-of-abdominal-germ-cell-tumors-gcts-a-pilot-study-with-pei-chemotherapy-and-regional-deep-hyperthermia-rht-in-comparison-to-a-matched-cohort 2024-01-22T19:04:29+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/226-treatment-of-primary-recurrent-or-inadequately-resected-high-risk-soft-tissue-sarcomas-sts-of-adults-results-of-a-phase-ii-pilot-study-rht-95-of-neoadjuvant-chemotherapy-combined-with-regional-hyperthermia 2024-01-22T19:04:29+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/225-regional-hyperthermia-in-conjunction-with-definitive-radiotherapy-against-recurrent-or-locally-advanced-prostate-cancer-t3-pn0-m0 2024-01-22T19:04:30+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/224-temperature-data-and-specific-absorption-rates-in-pelvic-tumours-predictive-factors-and-correlations 2024-01-22T19:04:31+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/223-radiochemotherapy-combined-with-regional-pelvic-hyperthermia-induces-high-response-and-resectability-rates-in-patients-with-nonresectable-cervical-cancer-or-figo-iib-bulky 2024-01-22T19:04:31+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/222-pre-operative-radio-chemotherapy-plus-regional-hyperthermia-in-the-treatment-of-advanced-rectal-cancer-experience-with-radiation-dose-escalation 2024-01-22T19:04:32+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/221-phase-i-ii-trial-of-intravenous-doxil-and-whole-abdomen-hyperthermia-in-patients-with-refractory-ovarian-cancer 2024-01-22T19:04:33+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/220-preoperative-hyperthermia-combined-with-radiochemotherapy-in-locally-advanced-rectal-cancer-a-phase-ii-clinical-trial 2024-01-22T19:04:33+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/219-the-treatment-of-high-grade-soft-tissue-sarcomas-with-preoperative-thermoradiotherapy 2024-01-22T19:04:34+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/218-preoperative-radiochemotherapy-in-locally-advanced-or-recurrent-rectal-cancer-regional-radiofrequency-hyperthermia-correlates-with-clinical-parameters 2024-01-22T19:04:34+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/217-a-phase-i-ii-study-to-evaluate-radiation-therapy-and-hyperthermia-for-deep-seated-tumours-a-report-of-rtog-89-08 2024-01-22T19:04:35+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/216-efficacy-of-irradiation-and-external-hyperthermia-in-locally-advanced-hormone-refractory-or-radiation-recurrent-prostate-cancer-a-preliminary-report 2024-01-22T19:04:36+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/215-re-irradiation-and-external-hyperthermia-in-locally-advanced-radiation-recurrent-hormone-refractory-prostate-cancer-a-preliminary-report 2024-01-22T19:04:36+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/214-reirradiation-and-hyperthermia-in-rectal-carcinoma-a-retrospective-study-on-palliative-effect 2024-01-22T19:04:37+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/213-a-pilot-phase-ii-trial-of-concurrent-radiotherapy-chemotherapy-and-hyperthermia-for-locally-advanced-cervical-carcinoma 2024-01-22T19:04:38+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/212-neoadjuvant-chemotherapy-combined-with-regional-hyperthermia-rht-for-locally-advanced-primary-or-recurrent-high-risk-adult-soft-tissue-sarcomas-sts-of-adults-long-term-results-of-a-phase-ii-study 2024-01-22T19:04:39+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/211-ifosfamide-plus-etoposide-combined-with-regional-hyperthermia-in-patients-with-locally-advanced-sarcomas-a-phase-ii-study 2024-01-22T19:04:39+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/210-regional-pelvic-hyperthermia-as-an-adjunct-to-chemotherapy-oxaliplatin-folinic-acid-5-fluorouracil-in-pre-irradiated-patients-with-locally-recurrent-rectal-cancer-a-pilot-study 2024-01-22T19:04:40+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/209-prospective-assessment-of-quality-of-life-in-ovarian-cancer-patients-receiving-whole-abdomen-hyperthermia-and-liposomal-doxorubicin 2024-01-22T19:04:40+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/207-deep-regional-hyperthermia-comparison-between-the-annular-phased-array-and-the-sigma-60-applicator-in-the-same-patients 2024-01-22T19:04:41+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/206-a-phase-i-ii-study-of-combined-weekly-systemic-cisplatin-and-locoregional-hyperthermia-in-patients-with-previously-irradiated-recurrent-carcinoma-of-the-uterine-cervix 2024-01-22T19:04:42+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/205-response-to-neoadjuvant-chemotherapy-combined-with-regional-hyperthermia-predicts-long-term-survival-for-adult-patients-with-retroperitoneal-and-visceral-high-risk-soft-tissue-sarcomas 2024-01-22T19:04:42+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/204-combined-external-beam-irradiation-and-external-regional-hyperthermia-for-locally-advanced-adenocarcinoma-of-the-prostate 2024-01-22T19:04:43+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/203-a-pilot-study-of-preoperative-continuous-infusion-5-fluorouracil-external-microwave-hyperthermia-and-external-beam-radiotherapy-for-treatment-of-locally-advanced-unresectable-or-recurrent-rectal-cancer 2024-01-22T19:04:44+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/202-pathological-complete-response-and-sphincter-sparing-surgery-after-neoadjuvant-radiochemotherapy-with-regional-hyperthermia-for-locally-advanced-rectal-cancer-compared-with-radiochemotherapy-alone 2024-01-22T19:04:44+00:00 0.33 https://pyrexar.com/clinical-us/bsd-2000-clinical-studies/200-concomitant-radiotherapy-and-hyperthermia-for-primary-carcinoma-of-the-vagina-a-cohort-study 2024-01-22T19:04:45+00:00 0.33 https://pyrexar.com/knowledgebase-us/hyperthermia-faq?view=article&id=26:sales-agency&catid=16 2024-01-22T19:04:46+00:00 0.33 https://pyrexar.com/component/content/featured?Itemid=101 2024-01-22T19:04:46+00:00 0.33 https://pyrexar.com/nobile 2024-01-22T19:04:47+00:00 0.33 https://pyrexar.com/stm2015?view=article&id=96:astro-american-society-for-radiation-oncology&catid=21 2024-01-22T19:04:48+00:00 0.33 https://pyrexar.com/knowledgebase-us?view=article&id=25:company-profile&catid=16 2024-01-22T19:04:49+00:00 0.33 https://pyrexar.com/component/tags/tag/pancreas 2024-01-22T19:04:49+00:00 0.26 https://pyrexar.com/component/content/article/89-concomitant-rt-and-ht-for-primary-carcinoma-of-the-vagina?catid=26&Itemid=101 2024-01-22T19:04:50+00:00 0.26 https://pyrexar.com/component/tags/tag/radiotherapy?start=20 2024-01-22T19:04:51+00:00 0.26 https://pyrexar.com/component/content/article/94-hdr-brachytherapy-combined-with-interstitial-hyperthermia-in-locally-advanced-cervical-cancer-patients-initially-treated-with-concomitant-radiochemotherapy-a-phase-iii-study?catid=26&Itemid=101 2024-01-22T19:04:52+00:00 0.26 https://pyrexar.com/component/tags/tag/chemotherapy?start=20 2024-01-22T19:04:53+00:00 0.26 https://pyrexar.com/component/tags/tag/chemotherapy?start=40 2024-01-22T19:04:54+00:00 0.26 https://pyrexar.com/component/weblinks/weblink/28-family-overview-brochure-2016?catid=38&Itemid=101 2024-01-22T19:04:55+00:00 0.26 https://pyrexar.com/component/tags/tag/bsd-2000?start=20 2024-01-22T19:04:56+00:00 0.26 https://pyrexar.com/component/tags/tag/bsd-2000?start=40 2024-01-22T19:04:56+00:00 0.26 https://pyrexar.com/component/tags/tag/phase-ii?start=20 2024-01-22T19:04:57+00:00 0.26 https://pyrexar.com/component/tags/tag/ovarian 2024-01-22T19:04:58+00:00 0.26 https://pyrexar.com/component/tags/tag/phase-i-ii 2024-01-22T19:04:59+00:00 0.26 https://pyrexar.com/component/tags/tag/prostate 2024-01-22T19:05:00+00:00 0.26 https://pyrexar.com/component/tags/tag/germ-cell-tumor 2024-01-22T19:05:01+00:00 0.26 https://pyrexar.com/component/tags/tag/phase-i 2024-01-22T19:05:02+00:00 0.26 https://pyrexar.com/component/tags/tag/deep-seated-tumors 2024-01-22T19:05:03+00:00 0.26 https://pyrexar.com/component/tags/tag/pediatric 2024-01-22T19:05:04+00:00 0.26 https://pyrexar.com/component/tags/tag/rectum 2024-01-22T19:05:04+00:00 0.26 https://pyrexar.com/component/tags/tag/recurrent 2024-01-22T19:05:05+00:00 0.26 https://pyrexar.com/component/tags/tag/bsd-500 2024-01-22T19:05:06+00:00 0.26 https://pyrexar.com/component/tags/tag/vaginal 2024-01-22T19:05:07+00:00 0.26 https://pyrexar.com/knowledgebase-us/hyperthermia-faq?view=article&id=25:company-profile&catid=16 2024-01-22T19:05:08+00:00 0.26 https://pyrexar.com/onemoreyear 2024-01-22T19:05:09+00:00 0.26 https://pyrexar.com/nobile?view=article&id=98:welcome-to-pyrexar-medical&catid=21 2024-01-22T19:05:09+00:00 0.26 https://pyrexar.com/index.php 2024-01-22T19:05:10+00:00 0.26 https://pyrexar.com/stm2015?view=article&id=119:rsna-radiological-society-of-north-america&catid=21 2024-01-22T19:05:11+00:00 0.26 https://pyrexar.com/knowledgebase-us?view=article&id=7:about-us&catid=16 2024-01-22T19:05:12+00:00 0.26 https://pyrexar.com/component/tags/tag/hyperthermia 2024-01-22T19:05:13+00:00 0.21 https://pyrexar.com/knowledgebase-us/hyperthermia-faq?view=article&id=7:about-us&catid=16 2024-01-22T19:05:13+00:00 0.21 https://pyrexar.com/pyrexar-day 2024-01-22T19:05:14+00:00 0.21 https://pyrexar.com/hotstart 2024-01-22T19:05:15+00:00 0.21 https://pyrexar.com/knowledgebase-us?view=article&id=8:team&catid=16 2024-01-22T19:05:16+00:00 0.21 https://pyrexar.com/knowledgebase-us/hyperthermia-faq?view=article&id=8:team&catid=16 2024-01-22T19:05:17+00:00 0.17 https://pyrexar.com/pyrexar-day?view=article&id=191:join-us-at-the-orr-2018-in-moscow&catid=21 2024-01-22T19:05:17+00:00 0.17 https://pyrexar.com/hotstart?view=article&id=119:rsna-radiological-society-of-north-america&catid=21 2024-01-22T19:05:18+00:00 0.17 https://pyrexar.com/pyrexar-day?view=article&id=180:stop-by-our-booth-at-astro-2017&catid=21 2024-01-22T19:05:19+00:00 0.13 https://pyrexar.com/hotstart?view=article&id=96:astro-american-society-for-radiation-oncology&catid=21 2024-01-22T19:05:19+00:00 0.13 https://pyrexar.com/pyrexar-day?view=article&id=174:join-us-at-the-31st-annual-esho&catid=21 2024-01-22T19:05:20+00:00 0.11 https://pyrexar.com/hotstart?view=article&id=80:esho-european-society-of-thermal-medicine&catid=21 2024-01-22T19:05:21+00:00 0.11 https://pyrexar.com/pyrexar-day?view=article&id=182:pyrexar-brochure-downloads&catid=21 2024-01-22T19:05:22+00:00 0.09 https://pyrexar.com/500-upgrade 2024-01-22T19:05:23+00:00 0.07 https://pyrexar.com/gift-cards 2024-01-22T19:05:23+00:00 0.05 https://pyrexar.com/500-upgrade?view=article&id=182:pyrexar-brochure-downloads&catid=21 2024-01-22T19:05:24+00:00 0.05 https://pyrexar.com/500-upgrade?view=article&id=174:join-us-at-the-31st-annual-esho&catid=21 2024-01-22T19:05:25+00:00 0.04 https://pyrexar.com/500-upgrade?view=article&id=180:stop-by-our-booth-at-astro-2017&catid=21 2024-01-22T19:05:26+00:00 0.04 https://pyrexar.com/500-upgrade?view=article&id=191:join-us-at-the-orr-2018-in-moscow&catid=21 2024-01-22T19:05:26+00:00 0.03